Miltenyi Biomedicine presents primary analysis of the pivotal DALY 2-EU trial for second-line relapsed/refractory large B-cell lymphoma at the 67th American Society of Hematology (ASH) Annual Meeting

December 2025

Miltenyi Biomedicine will present new data from the DALY 2-EU study at the American Society of Hematology (ASH) Annual Meeting

November 2025

Miltenyi Biomedicine will share positive interim results from DALY II USA at the American Society of Hematology (ASH) Annual Meeting

December 2024